228259-08-3

Upstream product

• 864061-59-6 2-(2-methanesulfonyloxymethyl-4-methoxy-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 228259-05-0 ethyl 1-(2-hydroxymethyl-4-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylate 
• 228259-07-2 ethyl 1-(2-azidomethyl-4-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylate 

Downstream Products

• 228259-11-8 2-(2-aminomethyl-4-methoxy-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (2'-tert-butylsulfamoyl-biphenyl-4-yl)-amide 
• 228259-10-7 3-methyl-1-(2-azidomethyl-4-methoxyphenyl)-1H-pyrazole-5-(N-(4-(2-N-tert-butylsulfamido)phenyl)phenyl)carboxamide 
• 228259-09-4 2-(2-azidomethyl-4-methoxy-phenyl)-5-methyl-2H-pyrazole-3-carbonyl chloride 

Relevant academic research and scientific papers

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2′ -(aminosulfonyl)[1,1′-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Factor Xa, a serine protease, is at the critical juncture between the intrinsic and extrinsic pathways of the coagulation cascade. Inhibition of factor Xa has the potential to provide effective treatment for both venous and arterial thrombosis. We recentl

Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors

The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E